Gastrointestinal disturbance and effect of fecal microbiota transplantation in discharged COVID-19 patients.

Szczegóły
Abstrakt

Tytuł:: Gastrointestinal disturbance and effect of fecal microbiota transplantation in discharged COVID-19 patients.
Autorzy:: Liu F; Department of Epidemiology and Health Statistics, Fujian Provincial Key Laboratory of Environment Factors and Cancer, School of Public Health, Fujian Medical University, Fuzhou, China.
Ye S; Ganzhou Municipal Hospital, 49 Dagonglu, Ganzhou, 341000, People's Republic of China.
Zhu X; Department of Laboratory Center, The Affiliated People's Hospital of Jiangsu University, 8 Dianlilu, Zhenjiang, 212000, People's Republic of China.
He X; GanzhouShanjian Bio-Technology Co., Ltd., Ganzhou, China.
Wang S; GanzhouShanjian Bio-Technology Co., Ltd., Ganzhou, China.
Li Y; School of Pharmacrutical Sciences, Gannan Medical University, Ganzhou, China.
Lin J; Department of Laboratory Center, The Affiliated People's Hospital of Jiangsu University, 8 Dianlilu, Zhenjiang, 212000, People's Republic of China.
Wang J; GanzhouShanjian Bio-Technology Co., Ltd., Ganzhou, China.
Lin Y; GanzhouShanjian Bio-Technology Co., Ltd., Ganzhou, China.
Ren X; Ganzhou Municipal Hospital, 49 Dagonglu, Ganzhou, 341000, People's Republic of China.
Li Y; Ganzhou Municipal Hospital, 49 Dagonglu, Ganzhou, 341000, People's Republic of China. .
Deng Z; Department of Laboratory Center, The Affiliated People's Hospital of Jiangsu University, 8 Dianlilu, Zhenjiang, 212000, People's Republic of China. .
Źródło:: Journal of medical case reports [J Med Case Rep] 2021 Feb 08; Vol. 15 (1), pp. 60. Date of Electronic Publication: 2021 Feb 08.
Typ publikacji:: Journal Article; Case Reports
Język:: English
Imprint Name(s):: Original Publication: [London] : BioMed Central, [2007-
MeSH Terms:: B-Lymphocyte Subsets*
Fecal Microbiota Transplantation*
Gastrointestinal Microbiome*
COVID-19/*complications
Dysbiosis/*therapy
Gastrointestinal Diseases/*therapy
Aged ; Bacteroidetes ; Bifidobacterium ; COVID-19/immunology ; Dysbiosis/microbiology ; Faecalibacterium ; Female ; Gastrointestinal Diseases/microbiology ; Humans ; Male ; Middle Aged ; Patient Discharge ; Proteobacteria ; SARS-CoV-2 ; Young Adult
References:: J Virol. 2007 Aug;81(16):8692-706. (PMID: 17537853)
Cell Rep. 2019 Jul 2;28(1):245-256.e4. (PMID: 31269444)
N Engl J Med. 2003 May 15;348(20):1986-94. (PMID: 12682352)
Best Pract Res Clin Gastroenterol. 2017 Dec;31(6):643-648. (PMID: 29566907)
Gut. 2020 Jun;69(6):1141-1143. (PMID: 32102928)
PLoS Pathog. 2014 Feb 20;10(2):e1003829. (PMID: 24586144)
Gastroenterology. 2020 Jul;159(1):81-95. (PMID: 32251668)
Bioinformation. 2018 Dec 29;14(9):560-573. (PMID: 31223215)
Front Immunol. 2018 Nov 16;9:2640. (PMID: 30505304)
Sci Adv. 2017 Nov 15;3(11):eaao4966. (PMID: 29152574)
Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264)
Microbiome. 2018 Jan 10;6(1):9. (PMID: 29321057)
Lancet Infect Dis. 2020 Sep;20(9):1004-1005. (PMID: 32645295)
Lancet Respir Med. 2020 May;8(5):475-481. (PMID: 32105632)
Nat Med. 2020 Apr;26(4):502-505. (PMID: 32284613)
J Infect Dis. 2020 May 11;221(11):1762-1769. (PMID: 32227123)
Nature. 2007 Oct 18;449(7164):811-8. (PMID: 17943117)
ISME J. 2017 Apr;11(4):841-852. (PMID: 28045459)
JAMA. 2020 Mar 17;323(11):1061-1069. (PMID: 32031570)
Mucosal Immunol. 2009 Mar;2(2):100-2. (PMID: 19129753)
Nat Commun. 2020 May 11;11(1):2354. (PMID: 32393794)
J Virol. 2016 Apr 29;90(10):4981-4989. (PMID: 26937040)
Annu Rev Med. 2019 Jan 27;70:335-351. (PMID: 30403550)
Proc Natl Acad Sci U S A. 2011 Mar 29;108(13):5354-9. (PMID: 21402903)
Nature. 2020 May;581(7809):465-469. (PMID: 32235945)
Microbiologyopen. 2019 Dec;8(12):e939. (PMID: 31568677)
Nature. 2018 Oct;562(7728):583-588. (PMID: 30356187)
EBioMedicine. 2019 Jun;44:730-740. (PMID: 30940601)
Gastroenterology. 2020 Sep;159(3):944-955.e8. (PMID: 32442562)
Cell. 2006 Feb 24;124(4):837-48. (PMID: 16497592)
Nature. 2012 Jul 25;487(7408):477-81. (PMID: 22837003)
Lancet. 2020 Feb 15;395(10223):507-513. (PMID: 32007143)
Gastroenterology. 2020 May;158(6):1831-1833.e3. (PMID: 32142773)
Front Microbiol. 2017 Dec 11;8:2430. (PMID: 29321764)
Grant Information:: 81970156 National Natural Science foundation of China; 81970118 National Natural Science foundation of China
Contributed Indexing:: Keywords: COVID-19; FMT; Infection; Microbiome
Entry Date(s):: Date Created: 20210209 Date Completed: 20210222 Latest Revision: 20231031
Update Code:: 20240104
PubMed Central ID:: PMC7868905
DOI:: 10.1186/s13256-020-02583-7
PMID:: 33557941
: Czasopismo naukowe

Full Text Finder

Background: To investigate the potential beneficial effect of fecal microbiota transplantation (FMT) on gastrointestinal symptoms, gut dysbiosis and immune status in discharged COVID-19 patients.
Case Presentation: A total of 11 COVID-19 patients were recruited in April, 2020, about one month on average after they were discharged from the hospital. All subjects received FMT for 4 consecutive days by oral capsule administrations with 10 capsules for each day. In total, 5 out of 11 patients reported to be suffered from gastrointestinal symptoms, which were improved after FMT. After FMT, alterations of B cells were observed, which was characterized as decreased naive B cell (P = 0.012) and increased memory B cells (P = 0.001) and non-switched B cells (P = 0.012).The microbial community richness indicated by operational taxonomic units number, observed species and Chao1 estimator was marginally increased after FMT. Gut microbiome composition of discharged COVID-19 patients differed from that of the general population at both phylum and genera level, which was characterized with a lower proportion of Firmicutes (41.0%) and Actinobacteria (4.0%), higher proportion of Bacteroidetes (42.9%) and Proteobacteria (9.2%). FMT can partially restore the gut dysbiosis by increasing the relative abundance of Actinobacteria (15.0%) and reducing Proteobacteria (2.8%) at the phylum level. At the genera level, Bifidobacterium and Faecalibacterium had significantly increased after FMT.
Conclusions: After FMT, altered peripheral lymphocyte subset, restored gut microbiota and alleviated gastrointestinal disorders were observe, suggesting that FMT may serve as a potential therapeutic and rehabilitative intervention for the COVID-19.

Informacja